Total Payments
$13,388
2024 Payments
$2,030
Companies
41
Transactions
689
Medicare Patients
2,079
Medicare Billing
$293,532
Payment Breakdown by Category
Food & Beverage$11,923 (89.1%)
Travel$1,341 (10.0%)
Education$124.51 (0.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $11,923 | 674 | 89.1% |
| Travel and Lodging | $1,341 | 8 | 10.0% |
| Education | $124.51 | 7 | 0.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $3,416 | 171 | $0 (2024) |
| Janssen Research & Development, LLC | $1,577 | 14 | $0 (2022) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $1,229 | 72 | $0 (2024) |
| Janssen Biotech, Inc. | $978.70 | 54 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $906.07 | 58 | $0 (2024) |
| Gilead Sciences, Inc. | $709.64 | 41 | $0 (2024) |
| QOL Medical, LLC | $663.06 | 38 | $0 (2024) |
| Daiichi Sankyo Inc. | $580.44 | 32 | $0 (2024) |
| Valeant Pharmaceuticals North America LLC | $355.04 | 16 | $0 (2017) |
| PFIZER INC. | $333.13 | 42 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,030 | 93 | ABBVIE INC. ($625.73) |
| 2023 | $1,899 | 99 | AbbVie Inc. ($550.68) |
| 2022 | $3,580 | 115 | Janssen Research & Development, LLC ($1,577) |
| 2021 | $1,506 | 88 | AbbVie Inc. ($576.32) |
| 2020 | $820.76 | 50 | AbbVie Inc. ($263.82) |
| 2019 | $1,471 | 111 | AbbVie, Inc. ($242.28) |
| 2018 | $917.49 | 55 | AbbVie, Inc. ($264.26) |
| 2017 | $1,165 | 78 | Valeant Pharmaceuticals North America LLC ($355.04) |
All Payment Transactions
689 individual payment records from CMS Open Payments — Page 1 of 28
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $26.24 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/23/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $18.25 | General |
| Category: Gastroenterology | ||||||
| 12/18/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $21.42 | General |
| Category: IMMUNOLOGY | ||||||
| 12/16/2024 | IRONWOOD PHARMACEUTICALS, INC | Linzess (Drug) | Food and Beverage | Cash or cash equivalent | $23.44 | General |
| Category: GI | ||||||
| 12/12/2024 | Celltrion USA Inc. | ZYMFENTRA (Biological) | Food and Beverage | In-kind items and services | $20.29 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/11/2024 | AIMMUNE THERAPEUTICS, INC. | ZENPEP (Drug) | Food and Beverage | In-kind items and services | $29.01 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 12/06/2024 | Celltrion USA Inc. | ZYMFENTRA (Biological) | Food and Beverage | In-kind items and services | $7.91 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/02/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $17.77 | General |
| Category: IMMUNOLOGY | ||||||
| 11/21/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $28.61 | General |
| Category: IMMUNOLOGY | ||||||
| 11/21/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $21.94 | General |
| Category: IMMUNOLOGY | ||||||
| 11/20/2024 | IRONWOOD PHARMACEUTICALS, INC | Linzess (Drug) | Food and Beverage | Cash or cash equivalent | $22.01 | General |
| Category: GI | ||||||
| 11/19/2024 | QOL Medical, LLC | SUCRAID (Drug) | Food and Beverage | Cash or cash equivalent | $27.31 | General |
| Category: THERAPY FOR CSID | ||||||
| 11/11/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $21.50 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/07/2024 | AIMMUNE THERAPEUTICS, INC. | ZENPEP (Drug) | Food and Beverage | In-kind items and services | $29.57 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 11/04/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $16.57 | General |
| Category: INTERNAL MEDICINE | ||||||
| 10/31/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $23.39 | General |
| Category: Gastroenterology | ||||||
| 10/28/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $37.34 | General |
| Category: Gastroenterology | ||||||
| 10/22/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $22.44 | General |
| Category: IMMUNOLOGY | ||||||
| 10/17/2024 | QOL Medical, LLC | SUCRAID (Drug) | Food and Beverage | Cash or cash equivalent | $36.46 | General |
| Category: THERAPY FOR CSID | ||||||
| 10/16/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $18.35 | General |
| Category: VIROLOGY | ||||||
| 09/27/2024 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ, HUMIRA | Food and Beverage | In-kind items and services | $23.20 | General |
| Category: IMMUNOLOGY | ||||||
| 09/25/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $13.19 | General |
| Category: INTERNAL MEDICINE | ||||||
| 09/16/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $28.17 | General |
| Category: IMMUNOLOGY | ||||||
| 09/05/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $19.58 | General |
| 09/05/2024 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $16.94 | General |
| Category: GASTROENTEROLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 545 | 598 | $227,078 | $77,254 |
| 2022 | 11 | 566 | 642 | $239,981 | $87,002 |
| 2021 | 10 | 406 | 463 | $155,616 | $59,682 |
| 2020 | 12 | 562 | 666 | $209,024 | $69,594 |
Total Patients
2,079
Total Services
2,369
Medicare Billing
$293,532
Procedure Codes
50
All Medicare Procedures & Services
50 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Office | 2023 | 57 | 57 | $70,610 | $21,483 | 30.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 127 | 166 | $25,232 | $15,264 | 60.5% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Office | 2023 | 44 | 44 | $38,780 | $9,895 | 25.5% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Office | 2023 | 28 | 28 | $20,160 | $6,167 | 30.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 49 | 49 | $12,397 | $5,518 | 44.5% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Office | 2023 | 12 | 12 | $9,720 | $3,590 | 36.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 23 | 23 | $6,992 | $3,171 | 45.4% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2023 | 66 | 66 | $11,418 | $2,952 | 25.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 41 | 43 | $6,450 | $2,850 | 44.2% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 13 | 13 | $15,990 | $2,593 | 16.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 17 | 29 | $3,915 | $1,824 | 46.6% |
| 99152 | Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | Office | 2023 | 25 | 25 | $3,250 | $966.24 | 29.7% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 23 | 23 | $1,564 | $805.15 | 51.5% |
| 99153 | Use of a drug to induce depression of consciousness by physician performing a procedure, each additional 15 minutes | Office | 2023 | 20 | 20 | $600.00 | $175.45 | 29.2% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Office | 2022 | 53 | 53 | $66,190 | $19,896 | 30.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 140 | 188 | $28,576 | $16,897 | 59.1% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Office | 2022 | 57 | 57 | $50,590 | $15,038 | 29.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 62 | 62 | $15,686 | $6,682 | 42.6% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 40 | 41 | $12,464 | $6,349 | 50.9% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Office | 2022 | 22 | 23 | $16,560 | $5,518 | 33.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 66 | 66 | $9,900 | $4,354 | 44.0% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Office | 2022 | 13 | 13 | $10,530 | $4,169 | 39.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 36 | 62 | $8,370 | $3,498 | 41.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 30 | 30 | $6,420 | $2,071 | 32.3% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2022 | 35 | 35 | $6,055 | $1,722 | 28.4% |
About Dr. Rene Rivera, MD
Dr. Rene Rivera, MD is a Gastroenterology healthcare provider based in Chesapeake, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/18/2007. The National Provider Identifier (NPI) number assigned to this provider is 1356537054.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Rene Rivera, MD has received a total of $13,388 in payments from pharmaceutical and medical device companies, with $2,030 received in 2024. These payments were reported across 689 transactions from 41 companies. The most common payment nature is "Food and Beverage" ($11,923).
As a Medicare-enrolled provider, Rivera has provided services to 2,079 Medicare beneficiaries, totaling 2,369 services with total Medicare billing of $293,532. Data is available for 4 years (2020–2023), covering 50 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Chesapeake, VA
- Active Since 09/18/2007
- Last Updated 02/27/2025
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1356537054
Products in Payments
- TREMFYA (Drug) $1,601
- XIFAXAN (Drug) $1,276
- HUMIRA (Biological) $808.34
- RINVOQ (Biological) $765.12
- ENTYVIO (Biological) $692.04
- STELARA (Biological) $682.90
- INJECTAFER (Drug) $567.60
- Humira (Biological) $431.08
- LINZESS (Drug) $386.74
- ZEPOSIA (Drug) $347.45
- SUCRAID (Drug) $346.84
- SKYRIZI (Biological) $319.61
- Sucraid (Drug) $316.22
- MAVYRET (Drug) $288.57
- REMICADE (Biological) $271.44
- XELJANZ (Drug) $231.22
- DIFICID (Drug) $196.56
- DUPIXENT (Biological) $187.33
- Mavyret (Drug) $183.98
- Linzess (Drug) $183.06
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Chesapeake
Felix Tiongco, M.d, M.D
Gastroenterology — Payments: $32,272
Gastroenterology $32,272
Walid Makdisi, M.d, M.D
Gastroenterology — Payments: $17,065
Gastroenterology $17,065
Dr. Jeremy Domanski, M.d, M.D
Gastroenterology — Payments: $13,883
Gastroenterology $13,883
Dr. Douglas Howerton, M.d, M.D
Gastroenterology — Payments: $13,365
Gastroenterology $13,365
Shoba Mendu, M.d, M.D
Gastroenterology — Payments: $12,648
Gastroenterology $12,648
Dr. Gary Payman, M.d, M.D
Gastroenterology — Payments: $11,281
Gastroenterology $11,281